一个功能性祖先相关的调节性单元型会影响CYP2D6的表达
1Drug Metabolism and Pharmacokinetics & Modeling, Takeda Development Center Americas, Incorporation, Cambridge, MA, USA. Michael.McCoy1@Takeda.com.
The pharmacogenomics journal
|February 17, 2026
概括
通过细胞P450 (CYP) 酶影响药物代谢的遗传变异对于个性化医学至关重要. 这项研究强调了CYP2D6的祖先特异性调节变异,影响药物反应,并需要更新药物遗传学测试.
科学领域:
- 药物基因组学 药物基因组学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 细胞染色体P450 (CYP) 酶对于大多数药物代谢至关重要.
- 对于影响不同人群中CYP介导药物代谢的调节性遗传变异的理解有限.
- 以前的研究主要集中在编码变体上,忽视了监管变化的影响.
研究的目的:
- 通过使用表达量化特征位点 (eQTL) 数据,全面分析54个cytochrome P450 (CYP) 基因的调节变异.
- 确定具有显著调节变异的特定CYP基因,并描述它们的功能和人口特异性影响.
- 评估是否需要将祖先特定的监管变异纳入药物遗传学测试策略.
主要方法:
- 利用基因型-组织表达 (GTEx) 数据库分析54个CYP基因的eQTL.
- 在基中进行功能分析,以预测已识别的变异对转录因子结合和染色质可访问性的影响.
- 研究了与已知的功能性等位基因相关的关键变异的种群分层和链接不平衡.
主要成果:
- CYP2D6表现出最广泛的调控变异,有249个已识别的变异,其中包括两种高效变异在强度链接不平衡.
- 在基分析表明,一种变种破坏了可访问的染色体区域内的众多转录因子结合位.
- 这些高频变异 (45%的东亚人与2.5%的欧洲人) 与功能减少的CYP2D6*10等位基因密切相关.
结论:
- 祖先特异性的调节变异显著导致药物代谢的个体间变异.
- 在CYP2D6中确定的调节变异具有相当大的群体特异频率和功能影响.
- 必须更新药物遗传测试策略,以包括这些祖先特定的监管变体,以提高药物的有效性和安全性.
相关概念视频
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
20
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
20
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
18
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
18
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24
Principles of Pharmacogenetics: Types of Genetic Variants
22
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
22
Pharmacogenetics of Drug Metabolism: Overview
23
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
23
Pharmacogenomics: Identification of New Drug Targets
20
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
20


